Cost-effectiveness of filgrastim-sndz as primary prophylaxis (PP) versus secondary prophylaxis (SP) to prevent chemotherapy-induced febrile neutropenia (FN) in breast cancer patients at intermediate risk.

Authors

Edward C. Li

Sandoz, Princeton, NJ

Edward C. Li, Dylan Mezzio, Kimberley J. Campbell, Andrew Spargo, Gary H. Lyman

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2021 ASCO Quality Care Symposium

bookmark_border

Association of primary prophylactic (PP) granulocyte-colony stimulating factor (G-CSF) use with chemotherapy dose modifications and relative dose intensity (RDI) among breast cancer patients receiving high-risk regimens for febrile neutropenia (FN).

First Author: Jaime Shaw

insert_chart_outlined

Poster

2019 ASCO Quality Care Symposium

bookmark_border

A cost-effectiveness analysis of primary prophylaxis (PP) versus secondary prophylaxis (SP) with biosimilar myeloid growth factors (MGFs) for preventing chemotherapy-induced febrile neutropenia (FN) in non-Hodgkin lymphoma (NHL) patients at intermediate risk.

First Author: Gary H. Lyman

insert_chart_outlined

Poster

2011 ASCO Annual Meeting

bookmark_border

Incidence of febrile neutropenia with docetaxel plus cyclophosphamide in a university-based breast oncology clinic.

First Author: A. Soni

insert_chart_outlined

Poster

2022 ASCO Annual Meeting

bookmark_border

Real-world effectiveness of prophylactic granulocyte colony-stimulating factor (G-CSF) early (week 1) and late (weeks 2-3) in the cycle for the prevention of febrile neutropenia (FN) among patients (pts) with breast cancer (BC) after high FN–risk chemotherapy (chemo).

First Author: Douglas W. Blayney